Form 4: Vertex Pharmaceuticals Executive Sells Shares Under Pre-Arranged Trading Plan

David Altshuler, EVP and Chief Scientific Officer at Vertex Pharmaceuticals, sold 15 shares of common stock at $478.56 per share under a pre-arranged trading plan.

Summary

• David Altshuler, an executive at Vertex Pharmaceuticals, sold 15 shares of the company's common stock.
• The sale occurred on November 15, 2024, at a price of $478.56 per share.
• This transaction was executed under a pre-arranged trading plan established on August 8, 2024, in accordance with Rule 10b5-1.
• Following the transaction, Mr. Altshuler directly owns 25,813 shares of Vertex Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: The document is a routine filing of an insider stock sale under a pre-arranged plan, which is neither positive nor negative.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use pre-arranged trading plans to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies to manage their stock holdings.
• The sale of 15 shares is a relatively small transaction and is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The impact on shareholders is expected to be minimal due to the small size of the transaction.

Key Dates

Keywords

Vertex Pharmaceuticals, insider trading, stock sale, Rule 10b5-1, executive, VRTX, David Altshuler